- Home
- VRNA vs KYMR Comparison
VRNA vs KYMR Comparison
Compare VRNA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNA
- KYMR
- Stock Information
- Founded
- VRNA 2005
- KYMR 2015
- Country
- VRNA United Kingdom
- KYMR United States
- Employees
- VRNA N/A
- KYMR N/A
- Industry
- VRNA Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- VRNA Health Care
- KYMR Health Care
- Exchange
- VRNA Nasdaq
- KYMR Nasdaq
- Market Cap
- VRNA 8.3B
- KYMR 3.1B
- IPO Year
- VRNA 2017
- KYMR 2020
- Fundamental
- Price
- VRNA $104.90
- KYMR $46.18
- Analyst Decision
- VRNA Buy
- KYMR Strong Buy
- Analyst Count
- VRNA 11
- KYMR 16
- Target Price
- VRNA $114.10
- KYMR $58.94
- AVG Volume (30 Days)
- VRNA 7.2M
- KYMR 877.8K
- Earning Date
- VRNA 08-07-2025
- KYMR 08-06-2025
- Dividend Yield
- VRNA N/A
- KYMR N/A
- EPS Growth
- VRNA N/A
- KYMR N/A
- EPS
- VRNA N/A
- KYMR N/A
- Revenue
- VRNA $118,535,000.00
- KYMR $58,885,000.00
- Revenue This Year
- VRNA $893.95
- KYMR $58.26
- Revenue Next Year
- VRNA $73.76
- KYMR N/A
- P/E Ratio
- VRNA N/A
- KYMR N/A
- Revenue Growth
- VRNA N/A
- KYMR N/A
- 52 Week Low
- VRNA $18.51
- KYMR $19.45
- 52 Week High
- VRNA $105.30
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- VRNA 70.69
- KYMR 61.48
- Support Level
- VRNA $104.58
- KYMR $43.66
- Resistance Level
- VRNA $104.91
- KYMR $45.83
- Average True Range (ATR)
- VRNA 1.88
- KYMR 1.50
- MACD
- VRNA 0.35
- KYMR -0.23
- Stochastic Oscillator
- VRNA 97.86
- KYMR 74.72
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.